WO2009147626A2 - Anhydrous amorphous form of imatinib mesylate - Google Patents
Anhydrous amorphous form of imatinib mesylate Download PDFInfo
- Publication number
- WO2009147626A2 WO2009147626A2 PCT/IB2009/052336 IB2009052336W WO2009147626A2 WO 2009147626 A2 WO2009147626 A2 WO 2009147626A2 IB 2009052336 W IB2009052336 W IB 2009052336W WO 2009147626 A2 WO2009147626 A2 WO 2009147626A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imatinib mesylate
- butanol
- water
- alcohol
- imatinib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to an anhydrous amorphous form of Imatinib mesylate and a process for preparation thereof.
- the structural formula of Imatinib mesylate is represented by formula (I)
- Imatinib 4-[(4-Methyl- l-piperazinyl)methy I]-ZV -
- Imatinib acts as tyrosine kinase inhibitor and protein kinase inhibitor. It also acts as single transduction inhibitor. It is highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia and certain forms of acute lymphoblastic leukemia. It inhibits the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. It is used as Antineoplastic. It is used in the treatment of all kind of cancer such as leukemia, solid turner, gastrointestinal cancer, prostate cancer, neurological cancer, myeloma and glioblastoma. It is also used in the treatment of, pulmonary fibrosis, rheumatoid arthritis and thrombocythemia.
- BCR-ABL the enzyme associated with chronic myelogenous leukemia and certain forms of acute lymphoblastic leukemia. It inhibits the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. It is used as Antineo
- Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
- a single molecule like Imatinib, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum, thermogravimetric analysis ( 1 TGA'), and differential scanning calorimetry ('DSC) which have been used to distinguish polymorphic forms.
- polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous physical properties compared to other crystalline forms of the same compound or complex.
- US Patent no. 6,894,051 discloses ⁇ -crystal form and ⁇ -crystal form of Imatinib mesylate.
- the process for preparation of ⁇ -crystal form comprise dijesting another amorphous or crystal forms with polar solvent such as MeOH, EtOH, acetone, DMF, DMAc, dioxane, water optionally seeding with ⁇ -crystal.
- US Patent no. 7,300,938 discloses Form Hl of Imatinib mesylate hydrate
- Amorphous Imatinib mesylate hydrate Amorphous Imatinib mesylate hydrate.
- the process for preparation of Form Hl comprise dissolving imatinib free base in a chlorinated solvent such as chloroform, MDC, EDC, adding methanesulfonic acid and isolating form Hl by filtration.
- the process for preparation of amorphous Imatinib mesylate hydrate comprises dissolving Imatinib mesylate in a mixture of methanol/water and then vacuum drying the solution.
- PCT application WO2005077933 discloses ⁇ 2 form of Imatinib mesylate.
- the process for prep of ⁇ 2 form comprise adding methane sulfonic acid to Imatinib base in IPA and heating at 40-80 0 C for 30 min and then cooling.
- PCT application WO2007023182 discloses delta ( ⁇ ) and epsilon ( ⁇ ) form of Imatinib mesylate.
- the process for prep of delta ( ⁇ ) form comprise dissolving Imatinib mesylate in water, charged it to microreactor, dried with nitrogen to get precipitates which is suspended in acetone/MeOH and aged at 55 0 C.
- the process for prep of epsilon( ⁇ ) form comprise dissolving Imatinib mesylate in water, charged it to microreactor, dried with nitrogen to get precipitates which is suspended in ethyl acetate/95% ethanol and aged at 55 0 C.
- Imatinib mesylate or its process for preparation.
- amorphous forms of a number of drugs exhibit different dissolution characteristics and in some cases different bio- availability patterns when compared to crystalline forms (Konne T., Chem. Pharm. Bull., 38, 2003 (1990)). For some therapeutic indications one bioavailability pattern may be favored over another.
- Amorphous forms of a number of drugs have been disclosed to exhibit different dissolution characteristics and in some cases different bioavailability patterns when compared to crystalline forms.
- the present invention aims to provide a novel amorphous form of Imatinib mesylate and a process for preparation thereof.
- the present invention is directed to a novel anhydrous amorphous form of Imatinib mesylate.
- Another object of the present invention is to provide a process for preparation of an anhydrous amorphous form of Imatinib mesylate.
- present invention provides an anhydrous amorphous form of Imatinib mesylate.
- the present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of [43] (i) adding Imatinib free base in a suitable solvent system;
- the present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of
- FIG. 1 shows the X-ray powder diffraction pattern of an anhydrous amorphous form of Imatinib mesylate (I).
- the present invention provides an anhydrous amorphous form of Imatinib mesylate having XRD characteristics as shown in FIG. 1.
- the present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate form Imatinib free base.
- the present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of [59] (i) adding Imatinib free base in a suitable solvent system;
- methane sulfonic acid is added to a mixture of Imatinib free base in a suitable solvent system.
- the reaction mixture is stirred for about 10 to 15 min to get clear solution.
- the solution is spry dried at about 6O 0 C to about 8O 0 C.
- the solid is isolated under anhydrous condition to give an anhydrous amorphous form of Imatinib mesylate.
- the suitable solvent system is selected from one component system, two component system and three component system.
- the one component system comprises single solvent which is selected from the group comprising an alcohol and water.
- the examples of alcohols includes but not limited to Ci -6 alcohol such as methanol, ethanol, propanol, butanol, isopropanol, sec-butanol and the like or mixtures thereof.
- the two component system comprises a homogeneous mixture of solvents wherein one solvent is an alcohol or water.
- the solvent is selected from alcohols, water, ketones, ethers, esters, nitriles, chlorinated solvents, aromatic hydrocarbons.
- solvent includes but not limited to methanol, ethanol, propanol, butanol, isopropanol, sec-butanol, water, acetone, methyl ethyl ketone, methyl isobutyl ketone, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, methyl tertbutyl ether, diisopropyl ether, diethyl ether, toluene, chlorobenzene, ace- tonitrile, ethyl acetate, methyl acetate, butyl acetate and the like or mixtures thereof.
- the combination of solvent is selected from alcohol/water, ketone/alcohol, ketone/ water, nitrile/alcohol, nitrile/water, chlorinated solvent/alcohol, ether/alcohol, aromatic hydrocarbon/alcohol.
- the examples of two component system includes but not limited to methanol/water, acetone/methanol, acetone/propanol, acetone/water, acetonitrile/ methanol, acetonitrile/water, methylethylketone/ethanol, dichloromethane/methanol, diethyl ether/methanol, toluene/methanol and the like or mixtures thereof.
- the three component system comprises a homogeneous mixture of solvents wherein one solvent is any alcohol or water.
- the solvent is selected from alcohols, water, ketones, ethers, esters, nitriles, chlorinated solvents, aromatic hydrocarbons or mixtures thereof as described above.
- the present invention provides another process for preparation of an anhydrous amorphous form of Imatinib mesylate form Imatinib mesyalte.
- the present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of
- Imatinib mesylate is added to a suitable solvent system and stirred for about 10 to 15 min.
- the clear solution is spry dried at about 6O 0 C to about 8O 0 C.
- the solid is isolated under anhydrous condition to give an anhydrous amorphous form of Imatinib mesylate.
- Imatinib free base (10.0 g) was added to methanol (30ml) and stirred for 10 to 15 min.
- Methane sulfonic acid (1.9 g) was added slowly to the above reaction mixture.
- the reaction mixture was stirred for 10 to 15 min to get clear solution.
- the solution was spray dried at about 6O 0 C to about 8O 0 C.
- the solid was isolated under anhydrous condition to get an anhydrous amorphous Imatinib mesylate (11.0 g)
Abstract
The present invention relates to an anhydrous amorphous form of Imatinib mesylate and a process for preparation thereof.
Description
Description Title of Invention: ANHYDROUS AMORPHOUS FORM OF
IMATINIB MESYLATE
Field of invention
[1]
[2] The present invention relates to an anhydrous amorphous form of Imatinib mesylate and a process for preparation thereof. [3] [4] The structural formula of Imatinib mesylate is represented by formula (I)
[6]
Background of the invention
[7]
[8] The chemical name of Imatinib is 4-[(4-Methyl- l-piperazinyl)methy I]-ZV -
[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, molecular formula is C2CiH31N7O and molecular weight is 493.60. The current pharmaceutical product containing this drug is being sold as its mesylate salt by Novartis using tradename Gleevec, in a form of oral tablets.
[9]
[10] Imatinib acts as tyrosine kinase inhibitor and protein kinase inhibitor. It also acts as single transduction inhibitor. It is highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia and certain forms of acute lymphoblastic leukemia. It inhibits the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. It is used as Antineoplastic. It is used in the treatment of all kind of cancer such as leukemia, solid turner, gastrointestinal cancer, prostate cancer, neurological cancer, myeloma and glioblastoma. It is also used in the treatment of, pulmonary fibrosis, rheumatoid arthritis and thrombocythemia.
[H]
[12] Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, like Imatinib, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint, and solid
state NMR spectrum, thermogravimetric analysis (1TGA'), and differential scanning calorimetry ('DSC) which have been used to distinguish polymorphic forms.
[13]
[14] The difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous physical properties compared to other crystalline forms of the same compound or complex.
[15]
[16] One of the most important physical properties of pharmaceutical compounds is their solubility in aqueous solution, particularly their solubility in the gastric juices of a patient. For example, where absorption through the gastrointestinal tract is slow, it is often desirable for a drug that is unstable to conditions in the patient's stomach or intestine to dissolve slowly so that it does not accumulate in a deleterious environment. Different crystalline forms or polymorphs of the same pharmaceutical compounds can and reportedly do have different aqueous solubility. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.
[17]
[18] A process for preparing Imatinib is set forth in U.S. Pat. No.5,521,184.
[19]
[20] US Patent no. 6,894,051 discloses α-crystal form and β-crystal form of Imatinib mesylate. The process for preparation of β-crystal form comprise dijesting another amorphous or crystal forms with polar solvent such as MeOH, EtOH, acetone, DMF, DMAc, dioxane, water optionally seeding with β-crystal.
[21]
[22] US Patent no. 7,300,938 discloses Form Hl of Imatinib mesylate hydrate and
Amorphous Imatinib mesylate hydrate. The process for preparation of Form Hl comprise dissolving imatinib free base in a chlorinated solvent such as chloroform, MDC, EDC, adding methanesulfonic acid and isolating form Hl by filtration. The process for preparation of amorphous Imatinib mesylate hydrate comprises dissolving Imatinib mesylate in a mixture of methanol/water and then vacuum drying the solution.
[23]
[24] PCT application WO2005077933 discloses α2 form of Imatinib mesylate. The process for prep of α2 form comprise adding methane sulfonic acid to Imatinib base in IPA and heating at 40-800C for 30 min and then cooling.
[25]
[26] PCT application WO2007023182 discloses delta (δ) and epsilon (ε) form of Imatinib mesylate. The process for prep of delta (δ) form comprise dissolving Imatinib mesylate in water, charged it to microreactor, dried with nitrogen to get precipitates which is suspended in acetone/MeOH and aged at 550C. The process for prep of epsilon(ε) form comprise dissolving Imatinib mesylate in water, charged it to microreactor, dried with nitrogen to get precipitates which is suspended in ethyl acetate/95% ethanol and aged at 550C.
[27]
[28] However, no patent/ patent application of prior art disclose an anhydrous amorphous
Imatinib mesylate or its process for preparation.
[29]
[30] It has been disclosed in prior art that the amorphous forms of a number of drugs exhibit different dissolution characteristics and in some cases different bio- availability patterns when compared to crystalline forms (Konne T., Chem. Pharm. Bull., 38, 2003 (1990)). For some therapeutic indications one bioavailability pattern may be favored over another. Amorphous forms of a number of drugs have been disclosed to exhibit different dissolution characteristics and in some cases different bioavailability patterns when compared to crystalline forms. The present invention aims to provide a novel amorphous form of Imatinib mesylate and a process for preparation thereof.
[31]
[32] The present invention is directed to a novel anhydrous amorphous form of Imatinib mesylate.
[33]
[34]
Object of the invention
[35]
[36] Therefore, it is an object of the present invention to provide an anhydrous amorphous form of Imatinib mesylate.
[37]
[38] Another object of the present invention is to provide a process for preparation of an anhydrous amorphous form of Imatinib mesylate.
[39]
Summary of the invention
[40]
[41] Accordingly, present invention, provides an anhydrous amorphous form of Imatinib mesylate.
[42] The present invention provides a process for preparation of an anhydrous amorphous
form of Imatinib mesylate comprising steps of [43] (i) adding Imatinib free base in a suitable solvent system;
[44] (ii) adding methane sulfonic acid;
[45] (iii) spray drying the solution obtained above in step (ii)
[46] The present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of
[47] (i) dissolving Imatinib meaylate in a suitable solvent system;
[48] (ii) spray drying the solution obtained above in step (i)
[49]
Brief description of the drawings [50] [51] FIG. 1 shows the X-ray powder diffraction pattern of an anhydrous amorphous form of Imatinib mesylate (I). [52]
Detailed description of the invention [53] [54] The present invention provides an anhydrous amorphous form of Imatinib mesylate having XRD characteristics as shown in FIG. 1. [55] [56] The present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate form Imatinib free base. [57] [58] The present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of [59] (i) adding Imatinib free base in a suitable solvent system;
[60] (ii) adding methane sulfonic acid;
[61] (iii) spray drying the solution obtained above in step (ii)
[62] [63] Thus, methane sulfonic acid is added to a mixture of Imatinib free base in a suitable solvent system. The reaction mixture is stirred for about 10 to 15 min to get clear solution. The solution is spry dried at about 6O0C to about 8O0C. The solid is isolated under anhydrous condition to give an anhydrous amorphous form of Imatinib mesylate. [64] [65] The suitable solvent system is selected from one component system, two component system and three component system. The one component system comprises single solvent which is selected from the group comprising an alcohol and water. The examples of alcohols includes but not limited to Ci-6 alcohol such as methanol, ethanol,
propanol, butanol, isopropanol, sec-butanol and the like or mixtures thereof.
[66]
[67] The two component system comprises a homogeneous mixture of solvents wherein one solvent is an alcohol or water. The solvent is selected from alcohols, water, ketones, ethers, esters, nitriles, chlorinated solvents, aromatic hydrocarbons. The examples of solvent includes but not limited to methanol, ethanol, propanol, butanol, isopropanol, sec-butanol, water, acetone, methyl ethyl ketone, methyl isobutyl ketone, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, methyl tertbutyl ether, diisopropyl ether, diethyl ether, toluene, chlorobenzene, ace- tonitrile, ethyl acetate, methyl acetate, butyl acetate and the like or mixtures thereof. The combination of solvent is selected from alcohol/water, ketone/alcohol, ketone/ water, nitrile/alcohol, nitrile/water, chlorinated solvent/alcohol, ether/alcohol, aromatic hydrocarbon/alcohol. The examples of two component system includes but not limited to methanol/water, acetone/methanol, acetone/propanol, acetone/water, acetonitrile/ methanol, acetonitrile/water, methylethylketone/ethanol, dichloromethane/methanol, diethyl ether/methanol, toluene/methanol and the like or mixtures thereof.
[68]
[69] The three component system comprises a homogeneous mixture of solvents wherein one solvent is any alcohol or water. The solvent is selected from alcohols, water, ketones, ethers, esters, nitriles, chlorinated solvents, aromatic hydrocarbons or mixtures thereof as described above.
[70]
[71] The present invention provides another process for preparation of an anhydrous amorphous form of Imatinib mesylate form Imatinib mesyalte.
[72]
[73] The present invention provides a process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of
[74] (i) dissolving Imatinib meaylate in a suitable solvent system;
[75] (ii) spray drying the solution obtained above in step (i)
[76]
[77] Imatinib mesylate is added to a suitable solvent system and stirred for about 10 to 15 min.
[78]
[79] The clear solution is spry dried at about 6O0C to about 8O0C. The solid is isolated under anhydrous condition to give an anhydrous amorphous form of Imatinib mesylate.
[80]
[81] The suitable solvent system taken is selected as mentioned earlier.
[82]
[83] The following example illustrates the invention further. It should be understood, however, that the invention is not confined to the specific limitations set forth in the individual example but rather to the scope of the appended claims.
[84]
[85] Example-1
[86] Preparation of an anhydrous amorphous form of Imatinib mesylate
[87] Imatinib free base (10.0 g) was added to methanol (30ml) and stirred for 10 to 15 min. Methane sulfonic acid (1.9 g) was added slowly to the above reaction mixture. The reaction mixture was stirred for 10 to 15 min to get clear solution. The solution was spray dried at about 6O0C to about 8O0C. The solid was isolated under anhydrous condition to get an anhydrous amorphous Imatinib mesylate (11.0 g)
[88] XRD is as shown in FIG. 1.
[89]
[90] Example-2
[91] Preparation of an anhydrous amorphous form of Imatinib mesylate
[92] Imatinib mesylate (10.0 g) was added to methanol (33ml) and stirred for about 10 to
15 min to get clear solution. The solution was spry dried at about 6O0C to about 8O0C. The solid was isolated under anhydrous condition to give an anhydrous amorphous Imatinib mesylate (10.0 g).
[93]
Claims
[Claim 1] What is claimed is
[Claim 2] 1. An anhydrous amorphous Imatinib mesylate.
[Claim 3]
[Claim 4] 2. An anhydrous amorphous Imatinib mesylate of claim 1, further characterized by an X-ray powder diffraction pattern as in FIG. 1.
[Claim 5]
[Claim 6] 3. A process of preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of
(i) adding Imatinib free base in a suitable solvent system;
(ii) adding methane sulfonic acid;
(iii) spray drying the solution obtained above in step (ii)
[Claim 7]
[Claim 8] 4. A process for preparation of an anhydrous amorphous form of Imatinib mesylate comprising steps of
(i) dissolving Imatinib meaylate in a suitable solvent system; (ii) spray drying the solution obtained above in step (i)
[Claim 9]
[Claim 10] 5. The process as claimed in claim 3 or 4, wherein the suitable solvent system is selected from one component system, two component system and three component system.
[Claim 11]
[Claim 12] 6. The process as claimed in claim 5, wherein one component system comprises single solvent selected from the group comprising alcohol and water.
[Claim 13]
[Claim 14] 7. The process as claimed in claim 6, wherein the alcohol is selected from Ci-6 alcohol such as methanol, ethanol, propanol, butanol, iso- propanol, sec-butanol, tert-butanol.
[Claim 15]
[Claim 16] 8. The process as claimed in claim 5, wherein two component system comprises a homogeneous mixture of solvents wherein one solvent is an alcohol or water.
[Claim 17]
[Claim 18] 9. The process as claimed in claim 5, wherein three component system comprises a homogeneous mixture of solvents wherein one solvent is any alcohol or water.
[Claim 19]
[Claim 20] 10. The process as claimed in claim 8 or 9, the solvent is selected from alcohols, water, ketones, ethers, esters, nitriles, chlorinated solvents, aromatic hydrocarbons or mixtures thereof.
[Claim 21]
[Claim 22] 11. The process as claimed in claim 10, wherein the solvent is selected from methanol, ethanol, propanol, butanol, isopropanol, sec-butanol, tert-butanol, water, acetone, methyl ethyl ketone, methyl isobutyl ketone, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, methyl tertbutyl ether, diisopropyl ether, diethyl ether, toluene, chlorobenzene, acetonitrile, ethyl acetate, methyl acetate, butyl acetate or mixtures thereof.
[Claim 23]
[Claim 24] 12. The process as claimed in claim 3 or 4, wherein spray drying is done at a temperature from about 6O0C to about 8O0C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1216/MUM/2008 | 2008-06-06 | ||
IN1216MU2008 | 2008-06-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009147626A2 true WO2009147626A2 (en) | 2009-12-10 |
WO2009147626A3 WO2009147626A3 (en) | 2011-01-27 |
Family
ID=41398625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/052336 WO2009147626A2 (en) | 2008-06-06 | 2009-06-03 | Anhydrous amorphous form of imatinib mesylate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009147626A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011157450A1 (en) | 2010-06-18 | 2011-12-22 | Krka, D. D., Novo Mesto | New polymorphic form of imatinib base and preparation of salts thereof |
ITMI20111309A1 (en) * | 2011-07-14 | 2013-01-15 | Italiana Sint Spa | PREPARATION PROCEDURE OF IMATINIB MESILATO |
CN103450153A (en) * | 2012-05-29 | 2013-12-18 | 广东东阳光药业有限公司 | Preparation method of anhydrous amorphous imatinib mesylate |
WO2017129624A1 (en) | 2016-01-25 | 2017-08-03 | Krka, D.D., Novo Mesto | Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136510A2 (en) * | 2006-04-27 | 2007-11-29 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha |
US20090181977A1 (en) * | 2008-01-10 | 2009-07-16 | Actavis Group Ptc Ehf | Anhydrous Amorphous Imatinib Mesylate |
US20090264438A1 (en) * | 2006-04-27 | 2009-10-22 | Alexandr Jegorov | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha |
-
2009
- 2009-06-03 WO PCT/IB2009/052336 patent/WO2009147626A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136510A2 (en) * | 2006-04-27 | 2007-11-29 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha |
US20090264438A1 (en) * | 2006-04-27 | 2009-10-22 | Alexandr Jegorov | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha |
US20090181977A1 (en) * | 2008-01-10 | 2009-07-16 | Actavis Group Ptc Ehf | Anhydrous Amorphous Imatinib Mesylate |
Non-Patent Citations (1)
Title |
---|
'The Effect of Spray-Drying Feed Temperature and Subsequent Crystallization Conditions on the Physical Form of Lactose' AAPS PHARMSCITECH, [Online] vol. 3, no. 4, 2002, Retrieved from the Internet: <URL:www.springerlink.com/content/m25g8465r 67v571v/fulltext.pdf> * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011157450A1 (en) | 2010-06-18 | 2011-12-22 | Krka, D. D., Novo Mesto | New polymorphic form of imatinib base and preparation of salts thereof |
ITMI20111309A1 (en) * | 2011-07-14 | 2013-01-15 | Italiana Sint Spa | PREPARATION PROCEDURE OF IMATINIB MESILATO |
EP2546247A1 (en) * | 2011-07-14 | 2013-01-16 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Imatinib mesylate preparation procedure |
CN103450153A (en) * | 2012-05-29 | 2013-12-18 | 广东东阳光药业有限公司 | Preparation method of anhydrous amorphous imatinib mesylate |
WO2017129624A1 (en) | 2016-01-25 | 2017-08-03 | Krka, D.D., Novo Mesto | Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
WO2009147626A3 (en) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102325775B1 (en) | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine | |
US8227477B2 (en) | Nilotinib HCl crystalline forms | |
WO2018196687A1 (en) | New crystal form of lenvatinib methanesulfonate and preparation method thereof | |
US7947699B2 (en) | Anhydrous amorphous imatinib mesylate | |
WO2014008270A1 (en) | Solid state form of vemurafenib choline salt | |
WO2009147626A2 (en) | Anhydrous amorphous form of imatinib mesylate | |
WO2011023146A1 (en) | Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions | |
US20200216427A1 (en) | Solid state forms of entrectinib | |
KR101501253B1 (en) | Crystalline Febuxostat Pidolate Salt and Method for Preparing Thereof | |
US10202364B2 (en) | Forms and compositions of an ERK inhibitor | |
US11339164B2 (en) | Crystalline form E1 of larotrectinib ethanesulfonate | |
US10206874B2 (en) | Rufinamide solid dispersion | |
WO2011100325A2 (en) | Polymorphs of sunitinib salts | |
CN113149998A (en) | Amorphous or crystalline forms of 2-indoline spirocyclic ketones or salts, solvates thereof | |
WO2019167068A1 (en) | Novel polymorphs of ribociclib succinate | |
KR20150084155A (en) | Crystalline form of N-((1-(3-(1,2,3-triazol-1-yl)propyl)piperidine-4-yl)methyl)-4-amino-5-choloro-2-methoxybenzamide derivatives and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09757974 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09757974 Country of ref document: EP Kind code of ref document: A2 |